SAN DIEGO, Sept. 24, 2026 /PRNewswire/ — Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its concurrent public offerings of 7,857,143…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
